In ovarian cancer cells, Activin-A treatment promotes EMT via canonical SMAD2/3 signaling together with SMAD4 (57), whereas in colon and breast cancer cells, it has been reported to promote EMT and cell migration or invasiveness independently of SMAD4 (7, 58). This evidence concerns the gene SMAD4 and breast carcinoma.